Optimizing therapy in the modern age : differences in length of maintenance therapy in acute lymphoblastic leukemia
© 2021 by The American Society of Hematology..
A majority of children and young adults with acute lymphoblastic leukemia (ALL) are cured with contemporary multiagent chemotherapy regimens. The high rate of survival is largely the result of 70 years of randomized clinical trials performed by international cooperative groups. Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years that includes central nervous system (CNS) prophylaxis, primarily consisting of CNS-penetrating systemic agents and intrathecal therapy. Although the treatment backbones vary among cooperative groups, the same agents are used, and the outcomes are comparable. ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase. Historically, a few cooperative groups treated boys with 1 more year of maintenance therapy than girls; however, most groups treated boys and girls with equal therapy lengths. This practice arose because of inferior survival in boys with older less-intensive regimens. The extra year of therapy added significant burden to patients and families and involved short- and long-term risks that were potentially life threatening and debilitating. The Children's Oncology Group recently changed its approach as part of its current generation of trials in B-cell ALL and now treats boys and girls with the same duration of therapy. We discuss the rationale behind this change, review the data and differences in practice across cooperative groups, and provide our perspective regarding the length of maintenance therapy.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
---|---|
Enthalten in: |
Blood - 137(2021), 2 vom: 14. Jan., Seite 168-177 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Teachey, David T [VerfasserIn] |
---|
Links: |
---|
Themen: |
Journal Article |
---|
Anmerkungen: |
Date Completed 19.04.2021 Date Revised 15.01.2022 published: Print Citation Status MEDLINE |
---|
doi: |
10.1182/blood.2020007702 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314504451 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314504451 | ||
003 | DE-627 | ||
005 | 20231225152856.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1182/blood.2020007702 |2 doi | |
028 | 5 | 2 | |a pubmed24n1048.xml |
035 | |a (DE-627)NLM314504451 | ||
035 | |a (NLM)32877503 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Teachey, David T |e verfasserin |4 aut | |
245 | 1 | 0 | |a Optimizing therapy in the modern age |b differences in length of maintenance therapy in acute lymphoblastic leukemia |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.04.2021 | ||
500 | |a Date Revised 15.01.2022 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021 by The American Society of Hematology. | ||
520 | |a A majority of children and young adults with acute lymphoblastic leukemia (ALL) are cured with contemporary multiagent chemotherapy regimens. The high rate of survival is largely the result of 70 years of randomized clinical trials performed by international cooperative groups. Contemporary ALL therapy usually consists of cycles of multiagent chemotherapy administered over 2 to 3 years that includes central nervous system (CNS) prophylaxis, primarily consisting of CNS-penetrating systemic agents and intrathecal therapy. Although the treatment backbones vary among cooperative groups, the same agents are used, and the outcomes are comparable. ALL therapy typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-intensity maintenance phase. Historically, a few cooperative groups treated boys with 1 more year of maintenance therapy than girls; however, most groups treated boys and girls with equal therapy lengths. This practice arose because of inferior survival in boys with older less-intensive regimens. The extra year of therapy added significant burden to patients and families and involved short- and long-term risks that were potentially life threatening and debilitating. The Children's Oncology Group recently changed its approach as part of its current generation of trials in B-cell ALL and now treats boys and girls with the same duration of therapy. We discuss the rationale behind this change, review the data and differences in practice across cooperative groups, and provide our perspective regarding the length of maintenance therapy | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
700 | 1 | |a Hunger, Stephen P |e verfasserin |4 aut | |
700 | 1 | |a Loh, Mignon L |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 137(2021), 2 vom: 14. Jan., Seite 168-177 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
773 | 1 | 8 | |g volume:137 |g year:2021 |g number:2 |g day:14 |g month:01 |g pages:168-177 |
856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2020007702 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 137 |j 2021 |e 2 |b 14 |c 01 |h 168-177 |